紫杉醇联合顺铂新辅助化疗在局部晚期宫颈癌中的应用价值分析  

Analyzing Value of Paclitaxel Plus Cisplatin Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer

作　　者：梁真娇[1] 

机构地区：[1]南方医科大学附属小榄医院妇产科,广东中山528415

出　　处：《潍坊医学院学报》2016年第3期218-220,共3页Acta Academiae Medicinae Weifang

摘　　要：目的分析紫杉醇联合顺铂新辅助化疗在局部晚期宫颈癌中的应用价值。方法选取102例局部晚期宫颈癌患者随机分为治疗组和对照组,治疗组患者给予紫杉醇联合顺铂新辅助化疗后手术治疗,对照组患者仅给予手术治疗,比较两组患者临床疗效。结果治疗组患者临床疗效CR率+PR率为84.31%,优于对照组患者的41.18%,治疗组患者阴道切缘阳性率、淋巴结阳性率、宫旁累及率、脉管浸润率较对照组患者均显著下降,治疗组患者消化道、骨髓抑制Ⅰ,Ⅱ反应较对照组患者显著提高,差异均具有统计学意义(P<0.05)。结论紫杉醇联合顺铂新辅助化疗能够提高局部晚期宫颈癌的临床疗效,降低术后阴道切缘阳性率、淋巴结阳性率、宫旁累及率、脉管浸润率,毒副反应在可耐受范围内。Objective To analysis value of paclitaxel plus cisplatin neoadjuvant chemotherapy in locally advanced cervical cancer. Methods One hundred and two cases with locally advanced cervical cancer were randomly divided into treatment and control groups. The treatment group were received ＂ paclitaxel ＋ cisplatin＂ new adjuvant chemotherapy before surgery,patients in the control group only received surgery. To compare the clinical efficacy and adverse reactions of the two groups. Results The CR ＋ PR rate in the treatment group was 84. 31% better than the 41. 18% in the control group. The rate of vaginal positive surgical margin,positive lymph nodes,parametrial involvement and vascular invasion were significantly decreased campared with the control group,but the gastrointestinal,bone marrow suppressionⅠ,Ⅱreactions were significantly increased（P〈0. 05）. Conclusion ＂ paclitaxel ＋ cisplatin＂ neoadjuvant chemotherapy in locally advanced cervical cancer can improve the clinical efficacy,reduce postoperative vaginal positive surgical margin rate,the rate of positive lymph nodes,parametrial involvement and vascular invasion rate,toxicity within tolerable range,is worthy of further promotion in clinical practice.

关 键 词：紫杉醇 顺铂 晚期宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]